Benzinga | Aug 4, 2021 08:12AM EDT

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $216

Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target from $196 to $216.